HLA-DR alleles determine responsiveness to Borrelia burgdorferi antigens in a mouse model of self-perpetuating arthritis

Arthritis and Rheumatism

Volumn 60, Issue 12, 2009, Pages 3831-3840

  Iliopoulou, Bettina Panagiota ^a   Guerau de Arellano, Mireia ^a   Huber, Brigitte T ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; GAMMA INTERFERON; HLA DR ANTIGEN; OUTER SURFACE PROTEIN A;

ALLELE; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BORRELIA BURGDORFERI; CELLULAR IMMUNITY; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; HLA DR GENE; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYME DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; T LYMPHOCYTE; TH1 CELL; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, SURFACE; ARTHRITIS, INFECTIOUS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL VACCINES; BORRELIA BURGDORFERI; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HLA-DR ANTIGENS; HUMANS; INTERFERON-GAMMA; LIPOPROTEINS; LYME DISEASE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 73249130223     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.25005     Document Type: Article

References (41)

1. Steere AC, Levin RE, Molloy PJ, Kalish RA, Abraham JH III, Liu NY, et al. Treatment of Lyme arthritis. Arthritis Rheum 1994;37: 878-88.
2. Carlson D, Hernandez J, Bloom BJ, Coburn J, Aversa JM, Steere AC. Lack of Borrelia burgdorferi DNA in synovial samples from patients with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum 1999;42:2705-9.
3. Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis [review]. Arthritis Rheum 2006;54:3079-86.
4. Kalish RA, Leong JM, Steere AC. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun 1993;61:2774-9.
5. Kalish RA, Leong JM, Steere AC. Early and late antibody responses to full-length and truncated constructs of outer surface protein A of Borrelia burgdorferi in Lyme disease. Infect Immun 1995;63:2228-35.
6. Steere AC, Glickstein L. Elucidation of Lyme arthritis. Nat Rev Immunol 2004;4:143-52.
7. Steere AC, Klitz W, Drouin EE, Falk BA, Kwok WW, Nepom GT, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 2006;203:961-71.
8. Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a structural perspective. Nat Rev Immunol 2006;6:271-82.
9. Steere AC, Falk B, Drouin EE, Baxter-Lowe LA, Hammer J, Nepom GT. Binding of outer surface protein A and human lymphocyte function-associated antigen 1 peptides to HLA-DR molecules associated with antibiotic treatment-resistant Lyme arthritis. Arthritis Rheum 2003;48:534-40.
10. Gross DM, Forsthuber T, Tary-Lehmann M, Etling C, Ito K, Nagy ZA, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998;281:703-6.
11. Guerau-de-Arellano M, Huber BT. Development of autoimmunity in Lyme arthritis. Curr Opin Rheumatol 2002;14:388-93.
12. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med 2001;7:899-905.
13. Ridgway WM, Fathman CG. MHC structure and autoimmune T cell repertoire development. Curr Opin Immunol 1999;11:638-42.
14. Iliopoulou BP, Huber BT. Emergence of chronic Lyme arthritis: putting the breaks on CD28 costimulation. Immunopharmacol Immunotoxicol 2008:1-12.
15. Iliopoulou BP, Alroy J, Huber BT. CD28 deficiency exacerbates joint inflammation upon Borrelia burgdorferi infection, resulting in the development of chronic Lyme arthritis. J Immunol 2007; 179:8076-82.
16. Ito K, Bian HJ, Molina M, Han J, Magram J, Saar E, et al. HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis. J Exp Med 1996;183:2635-44.
17. Kotsch K, Wehling J, Blasczyk R. Sequencing of HLA class II genes based on the conserved diversity of the non-coding regions: sequencing based typing of HLA-DRB genes. Tissue Antigens 1999;53:486-97.
18. Coburn J, Barthold SW, Leong JM. Diverse Lyme disease spirochetes bind integrin αIIbβ3 on human platelets. Infect Immun 1994;62:5559-67.
19. Coburn J, Leong JM, Erban JK. Integrin αIIbβ3 mediates binding of the Lyme disease agent Borrelia burgdorferi to human platelets. Proc Natl Acad Sci U S A 1993;90:7059-63.
20. Iliopoulou BP, Alroy J, Huber BT. Persistent arthritis in Borrelia burgdorferi-infected HLA-DR4-positive CD28-negative mice post-antibiotic treatment. Arthritis Rheum 2008;58:3892-901.
21. Keane-Myers A, Nickell SP. Role of IL-4 and IFN-γ in modulation of immunity to Borrelia burgdorferi in mice. J Immunol 1995;155: 2020-8.
22. Kang I, Barthold SW, Persing DH, Bockenstedt LK. T-helper-cell cytokines in the early evolution of murine Lyme arthritis. Infect Immun 1997;65:3107-11.
23. Matyniak JE, Reiner SL. T helper phenotype and genetic susceptibility in experimental Lyme disease. J Exp Med 1995;181:1251-4.
24. Crandall H, Dunn DM, Ma Y, Wooten RM, Zachary JF, Weis JH, et al. Gene expression profiling reveals unique pathways associated with differential severity of Lyme arthritis. J Immunol 2006;177:7930-42.
25. Gross DM, Steere AC, Huber BT. T helper 1 response is dominant and localized to the synovial fluid in patients with Lyme arthritis. J Immunol 1998;160:1022-8.
26. Shin JJ, Glickstein LJ, Steere AC. High levels of inflammatory chemokines and cytokines in joint fluid and synovial tissue throughout the course of antibiotic-refractory Lyme arthritis. Arthritis Rheum 2007;56:1325-35.
27. Yssel H, Shanafelt MC, Soderberg C, Schneider PV, Anzola J, Peltz G. Borrelia burgdorferi activates a T helper type 1-like T cell subset in Lyme arthritis. J Exp Med 1991;174:593-601.
28. Alves C, Souza T, Meyer I, Toralles MB, Brites C. Immunogenetics and infectious diseases: special reference to the mayor histocompatibility complex. Braz J Infect Dis 2006;10:122-31.
29. Mangalam AK, Rajagopalan G, Taneja V, David CS. HLA class II transgenic mice mimic human inflammatory diseases. Adv Immunol 2008;97:65-147.
30. Abraham RS, David CS. Identification of HLA-class-II-restricted epitopes of autoantigens in transgenic mice. Curr Opin Immunol 2000;12:122-9.
31. Chen J, Field JA, Glickstein L, Molloy PJ, Huber BT, Steere AC. Association of antibiotic treatment-resistant Lyme arthritis with T cell responses to dominant epitopes of outer surface protein A of Borrelia burgdorferi. Arthritis Rheum 1999;42:1813-22.
32. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 1994;180:2353-8.
33. Drouin EE, Glickstein L, Kwok WW, Nepom GT, Steere AC. Searching for borrelial T cell epitopes associated with antibiotic-refractory Lyme arthritis. Mol Immunol 2008;45:2323-32.
34. Meyer AL, Trollmo C, Crawford F, Marrack P, Steere AC, Huber BT, et al. Direct enumeration of Borrelia-reactive CD4 T cells ex vivo by using MHC class II tetramers. Proc Natl Acad Sci U S A 2000;97:11433-8.
35. Munson EL, Du Chateau BK, Jensen JR, Callister SM, DeCoster DJ, Schell RF. Gamma interferon inhibits production of Anti-OspA borreliacidal antibody in vitro. Clin Diagn Lab Immunol 2002;9:1095-101.
36. Garcia-Ramos G, Tellez-Zenteno JF, Zapata-Zuniga M, Yamamoto-Furusho JK, Ruiz-Morales JA, Villarreal-Garza C, et al. HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis. Eur J Neurol 2003;10:707-10.
37. Monneaux F, Lozano JM, Patarroyo ME, Briand JP, Muller S. T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice. Eur J Immunol 2003;33:287-96.
38. Juhasz F, Kozma L, Stenszky V, Gyory F, Luckas G, Farid NR. Well differentiated thyroid carcinoma is associated with human lymphocyte antigen D-related 11 in Eastern Hungarians: a case of changing circumstances. Cancer 2005;104:1603-8.
39. Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis [review]. PLoS Genet 2008;4: e1000024.
40. Zeliszewski D, Golvano JJ, Gaudebout P, Dorval I, Freidel C, Gebuhrer L, et al. Implication of HLA-DR residues at positions 67, 71, and 86 in interaction between HLA-DR11 and peptide HA306-320. J Immunol 1993;151:6237-47.
41. Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, Valsasnini P, et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med 1995;181: 1847-55.